Can a poison become a cure? arsenic trioxide put to the test in blood cancer transplant

NCT ID NCT07737769

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding arsenic trioxide to a standard stem cell transplant can prevent the cancer from coming back in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls about 20 patients whose cancers have a specific genetic flaw (TP53 mutation). The main goal is to check the safety and best dose of arsenic trioxide in this setting, while also watching for signs that it might keep the cancer in remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
arsenic trioxide given alongside an allogeneic stem cell transplant
What this could lead to
If it works, this could point toward a way to prevent relapse and improve long-term survival for people with high-risk blood cancers.
What could go wrong
This is a very early, small phase I trial focused on safety and dosing, so it is unknown whether arsenic trioxide will actually prevent relapse. Arsenic trioxide can cause serious side effects, including heart rhythm problems and liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.